# Reassessing Benign ASXL1 Variants in Bohring–Opitz Syndrome: The Role of Population Databases in Variant Reinterpretation

**Authors:** Liliana Fernández-Hernández, Sergio Enríquez-Flores, Nancy L. Hernández-Martínez, Melania Abreu-González, Esther Lieberman-Hernández, Gerardo Rodríguez-González, Sinuhé Reyes-Ruvalcaba, Miriam E. Reyna-Fabián

PMC · DOI: 10.3390/genes17020231 · Genes · 2026-02-12

## TL;DR

This study uses structural modeling to reassess the significance of certain ASXL1 gene variants linked to Bohring–Opitz syndrome, showing how they might affect protein function.

## Contribution

The study introduces structural modeling as a tool to reinterpret ASXL1 missense variants previously classified as benign or uncertain.

## Key findings

- Structural modeling revealed that p.Q1448R alters polar interactions and introduces steric constraints near a conserved domain.
- Variants p.R265H and p.T297M disrupt stabilizing interactions in the DEUBAD domain, while p.Y358C affects a polar microenvironment.
- Except for p.T297M, all variants localized to evolutionarily conserved regions, suggesting potential functional impact.

## Abstract

Background/Objectives: ASXL1 is a chromatin-associated gene implicated in both hematologic malignancies and neurodevelopmental disorders, including Bohring–Opitz syndrome (BOS). Although many ASXL1 variants are well classified, a substantial proportion remain variants of uncertain significance (VUS), complicating molecular diagnosis and genetic counseling. The objective of this study was to evaluate whether structural context can inform the interpretation of selected ASXL1 missense variants in a clinical setting. Methods: We describe a 17-year-old female with clinical features consistent with BOS carrying the heterozygous ASXL1 variant p.Q1448R, currently classified as benign under ACMG/AMP guidelines. Three-dimensional in silico structural modeling was performed using AlphaFold3 and available crystallographic data. Three additional ASXL1 missense variants classified as VUS in ClinVar (p.R265H, p.T297M, and p.Y358C) were also analyzed. Evolutionary conservation, domain localization, and residue-level interactions were assessed. Results: Structural modeling indicated that the p.Q1448R substitution alters polar interactions and introduces a steric constraint near a conserved PHD-type zinc finger domain. Variants p.R265H and p.T297M affected stabilizing interactions within the DEUBAD, which is involved in BAP1 activation, while p.Y358C altered a polar microenvironment adjacent to a chromatin-interacting region. All analyzed variants, except p.T297M, localized to evolutionarily conserved regions. Conclusions: This study demonstrates that in silico structural analysis can provide complementary, domain-level insights for the interpretation of ASXL1 missense variants that remain classified as benign, likely benign or VUS under current frameworks. Such approaches may assist in prioritizing variants for further functional evaluation and refining molecular interpretation when experimental data are limited.

## Linked entities

- **Genes:** ASXL1 (ASXL transcriptional regulator 1) [NCBI Gene 171023]
- **Proteins:** BAP1 (BRCA1 associated deubiquitinase 1)
- **Diseases:** Bohring–Opitz syndrome (MONDO:0011510)

## Full-text entities

- **Genes:** UBB (ubiquitin B) [NCBI Gene 7314] {aka HEL-S-50}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, FOXK1 (forkhead box K1) [NCBI Gene 221937] {aka FOXK1L}, DNMT3A (DNA methyltransferase 3 alpha) [NCBI Gene 1788] {aka DNMT3A2, HESJAS, M.HsaIIIA, TBRS}, SRSF2 (serine and arginine rich splicing factor 2) [NCBI Gene 6427] {aka PR264, SC-35, SC35, SFRS2, SFRS2A, SRp30b}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, TET2 (tet methylcytosine dioxygenase 2) [NCBI Gene 54790] {aka IMD75, KIAA1546, MDS}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, NCOA1 (nuclear receptor coactivator 1) [NCBI Gene 8648] {aka F-SRC-1, KAT13A, RIP160, SRC1, bHLHe42, bHLHe74}, SETBP1 (SET binding protein 1) [NCBI Gene 26040] {aka MRD29, SEB}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, PPM1D (protein phosphatase, Mg2+/Mn2+ dependent 1D) [NCBI Gene 8493] {aka IDDGIP, JDVS, PP2C-DELTA, WIP1}, PTPN11 (protein tyrosine phosphatase non-receptor type 11) [NCBI Gene 5781] {aka BPTP3, CFC, JMML, METCDS, NS1, PTP-1D}, BAP1 (BRCA1 associated deubiquitinase 1) [NCBI Gene 8314] {aka HUCEP-13, KURIS, TPDS1, UBM2, UCHL2, UVM2}, KDM1B (lysine demethylase 1B) [NCBI Gene 221656] {aka AOF1, C6orf193, LSD2}, ASXL1 (ASXL transcriptional regulator 1) [NCBI Gene 171023] {aka BOPS, MDS}, SF3B1 (splicing factor 3b subunit 1) [NCBI Gene 23451] {aka Hsh155, MDS, PRP10, PRPF10, SAP155, SF3b155}
- **Diseases:** dental malalignment (MESH:D017760), facial dysmorphism (MESH:C565579), MDS (MESH:D009190), hematologic malignancies (MESH:D019337), AML (MESH:D015470), autosomal dominant disorders (MESH:D030342), exophthalmos (MESH:D005094), acanthosis nigricans (MESH:D000052), short stature (MESH:D006130), ID (MESH:C537985), BOS (MESH:C537419), brachydactyly (MESH:D059327), intrauterine growth restriction (MESH:D005317), injury to (MESH:D014947), clonal hematopoiesis of indeterminate (MESH:C536227), hirsutism (MESH:D006628), ulnar deviation (MESH:D010262), MPN (MESH:D009369), VUS (MESH:D065309), adiposity (MESH:D018205), joint hypermobility (MESH:D007593), hypertrichosis (MESH:D006983), infectious diseases (MESH:D003141), lower eyelid distichiasis (MESH:D005141), CMML (MESH:D015477), keratosis pilaris (MESH:C537412), autosomal dominant neurodevelopmental disorder (MESH:D002658), intellectual disability (MESH:D008607), hypotonia (MESH:D009123), hypertelorism (MESH:D006972)
- **Chemicals:** Asparagine (MESH:D001216), Zinc (MESH:D015032), acid (MESH:D000143), Methionine (MESH:D008715), Cysteine (MESH:D003545), Threonine (MESH:D013912), silica (MESH:D012822), Aspartic acid (MESH:D001224), thiol (MESH:D013438)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 32431590-C-T, tyrosine with cysteine, c.4343A>G, glutamine with arginine, Cys 2 His, arginine with histidine, Y358, R265H, p.Y358C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941326/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941326/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941326/full.md

---
Source: https://tomesphere.com/paper/PMC12941326